These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 22442395)

  • 21. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes.
    Roberts S; Barry E; Craig D; Airoldi M; Bevan G; Greenhalgh T
    BMJ Open; 2017 Nov; 7(11):e017184. PubMed ID: 29146638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
    Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
    Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of lifestyle and metformin interventions in DPP on bone density.
    Schwartz AV; Pan Q; Aroda VR; Crandall JP; Kriska A; Piromalli C; Wallia A; Temprosa M; Florez H;
    Osteoporos Int; 2021 Nov; 32(11):2279-2287. PubMed ID: 34086101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial.
    Moin T; Duru OK; Turk N; Chon JS; Frosch DL; Martin JM; Jeffers KS; Castellon-Lopez Y; Tseng CH; Norris K; Mangione CM
    J Gen Intern Med; 2019 Nov; 34(11):2652-2659. PubMed ID: 31471729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis.
    Glechner A; Keuchel L; Affengruber L; Titscher V; Sommer I; Matyas N; Wagner G; Kien C; Klerings I; Gartlehner G
    Prim Care Diabetes; 2018 Oct; 12(5):393-408. PubMed ID: 30076075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.
    Rittenhouse BE; Alolayan S; Eguale T; Segal AR; Doucette J
    Diabetes Obes Metab; 2024 Nov; 26(11):5097-5106. PubMed ID: 39143657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
    Salimi Y; Fotouhi A; Mohammad K; Mansournia N; Mansournia MA
    Arch Iran Med; 2017 Jan; 20(1):55-59. PubMed ID: 28112533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
    Anderson JM
    J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study.
    Luchsinger JA; Ma Y; Christophi CA; Florez H; Golden SH; Hazuda H; Crandall J; Venditti E; Watson K; Jeffries S; Manly JJ; Pi-Sunyer FX;
    Diabetes Care; 2017 Jul; 40(7):958-965. PubMed ID: 28500216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply.
    Rittenhouse BE; Alolayan S; Eguale T; Segal AR; Doucette J
    Prev Med; 2024 Jan; 178():107819. PubMed ID: 38092328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
    Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
    BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Goldberg RB; Orchard TJ; Crandall JP; Boyko EJ; Budoff M; Dabelea D; Gadde KM; Knowler WC; Lee CG; Nathan DM; Watson K; Temprosa M;
    Circulation; 2022 May; 145(22):1632-1641. PubMed ID: 35603600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
    Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
    BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS).
    ; Hamman RF; Horton E; Barrett-Connor E; Bray GA; Christophi CA; Crandall J; Florez JC; Fowler S; Goldberg R; Kahn SE; Knowler WC; Lachin JM; Murphy MB; Venditti E
    Diabetes; 2015 Mar; 64(3):989-98. PubMed ID: 25277389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
    Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
    Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.